Understanding Alcohol Dependence: Symptoms and Screening Tools

Alcohol dependence is a serious condition characterized by a strong compulsion to drink, withdrawal symptoms, tolerance, and loss of control over alcohol use. This vignette illustrates a classic scenario of alcohol dependence, with features of tolerance, withdrawals, neglect of other pleasures, and low mood associated with heavy chronic alcohol consumption. While depression can be a symptom of alcohol dependence, it is not the primary diagnosis.

The term alcohol abuse is being replaced by alcohol-use disorder or harmful drinking to describe patterns of alcohol use that cause physical or mental health damage. In this vignette, the woman likely has harmful use of alcohol, but the overall picture points to a diagnosis of alcohol dependence.

Withdrawal symptoms are a common feature of alcohol dependence, and the woman in this vignette would likely experience them if she suddenly stopped drinking. Social withdrawal is also an indicator of alcohol dependence, but it does not explain the entire pattern of symptoms and behavior presented.

A useful screening test for alcohol-use disorders is the CAGE questionnaire, which asks about cutting down, annoyance from others, guilt, and needing a drink first thing in the morning. Answering yes to two or more questions may indicate the presence of an alcohol-use disorder. Other screening tools include the FAST and AUDIT tests, which can be administered quickly in busy medical settings.

Overall, understanding the symptoms and screening tools for alcohol dependence is crucial for early detection and intervention.

To decrease the risk of relapse, it is recommended to continue antidepressant treatment for at least 6 months after remission of symptoms. Therefore, the correct response is to continue fluoxetine for at least 6 months at the same dose. It should be noted that in elderly patients, treatment should be continued for 12 months, and in those with a history of recurrent depression, treatment should be continued for 2 years. Stopping fluoxetine or tapering the dose over 2 weeks is not appropriate, as treatment should be continued for at least 6 months before considering stopping or tapering. When fluoxetine is stopped, it is recommended to taper the dose over 6-12 weeks to minimize the risk of withdrawal symptoms.

Selective serotonin reuptake inhibitors (SSRIs) are commonly used as the first-line treatment for depression. Citalopram and fluoxetine are the preferred SSRIs, while sertraline is recommended for patients who have had a myocardial infarction. However, caution should be exercised when prescribing SSRIs to children and adolescents. Gastrointestinal symptoms are the most common side-effect, and patients taking SSRIs are at an increased risk of gastrointestinal bleeding. Patients should also be aware of the possibility of increased anxiety and agitation after starting a SSRI. Fluoxetine and paroxetine have a higher propensity for drug interactions.

The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a warning regarding the use of citalopram due to its association with dose-dependent QT interval prolongation. As a result, citalopram and escitalopram should not be used in patients with congenital long QT syndrome, known pre-existing QT interval prolongation, or in combination with other medicines that prolong the QT interval. The maximum daily dose of citalopram is now 40 mg for adults, 20 mg for patients older than 65 years, and 20 mg for those with hepatic impairment.

When initiating antidepressant therapy, patients should be reviewed by a doctor after 2 weeks. Patients under the age of 25 years or at an increased risk of suicide should be reviewed after 1 week. If a patient responds well to antidepressant therapy, they should continue treatment for at least 6 months after remission to reduce the risk of relapse. When stopping a SSRI, the dose should be gradually reduced over a 4 week period, except for fluoxetine. Paroxetine has a higher incidence of discontinuation symptoms, including mood changes, restlessness, difficulty sleeping, unsteadiness, sweating, gastrointestinal symptoms, and paraesthesia.

When considering the use of SSRIs during pregnancy, the benefits and risks should be weighed. Use during the first trimester may increase the risk of congenital heart defects, while use during the third trimester can result in persistent pulmonary hypertension of the newborn. Paroxetine has an increased risk of congenital malformations, particularly in the first trimester.

In the management of alcohol withdrawal, decreasing doses of long-acting benzodiazepines are commonly used. This is because long-term alcohol use can cause an imbalance in the brain’s excitatory and inhibitory neurotransmitters, leading to symptoms of an overactive sympathetic nervous system when alcohol is suddenly stopped. These symptoms can include restlessness, sweating, tremors, and agitation, and can even progress to seizures and delirium tremens. Long-acting benzodiazepines, such as chlordiazepoxide or diazepam, potentiate the action of the inhibitory neurotransmitter GABA and can help mitigate the risk of seizures and other withdrawal symptoms. Carbamazepine, an anticonvulsant, may also be used as a second-line medication if benzodiazepines are not appropriate. Haloperidol, a typical antipsychotic, is not typically used in alcohol withdrawal as it does not reduce the risk of seizures. Lorazepam, a short-acting benzodiazepine, is also not typically used in this context as long-acting benzodiazepines are preferred for their longer half-life.

Alcohol withdrawal occurs when an individual who has been consuming alcohol chronically suddenly stops or reduces their intake. Chronic alcohol consumption enhances the inhibitory effects of GABA in the central nervous system, similar to benzodiazepines, and inhibits NMDA-type glutamate receptors. However, alcohol withdrawal leads to the opposite effect, resulting in decreased inhibitory GABA and increased NMDA glutamate transmission. Symptoms of alcohol withdrawal typically start at 6-12 hours and include tremors, sweating, tachycardia, and anxiety. Seizures are most likely to occur at 36 hours, while delirium tremens, which includes coarse tremors, confusion, delusions, auditory and visual hallucinations, fever, and tachycardia, peak at 48-72 hours.

Patients with a history of complex withdrawals from alcohol, such as delirium tremens, seizures, or blackouts, should be admitted to the hospital for monitoring until their withdrawals stabilize. The first-line treatment for alcohol withdrawal is long-acting benzodiazepines, such as chlordiazepoxide or diazepam, which are typically given as part of a reducing dose protocol. Lorazepam may be preferable in patients with hepatic failure. Carbamazepine is also effective in treating alcohol withdrawal, while phenytoin is said to be less effective in treating alcohol withdrawal seizures.

Alcohol Problem Drinking: Detection and Assessment

Alcohol problem drinking can have serious consequences on an individual’s health and well-being. Therefore, it is important to detect and assess problem drinking early on. Screening tools such as AUDIT, FAST, and CAGE can be used to identify individuals who may have hazardous or harmful alcohol consumption or alcohol dependence.

AUDIT is a 10-item questionnaire that takes about 2-3 minutes to complete. It has been shown to be superior to CAGE and biochemical markers for predicting alcohol problems. A score of 8 or more in men, and 7 or more in women, indicates a strong likelihood of hazardous or harmful alcohol consumption. A score of 15 or more in men, and 13 or more in women, is likely to indicate alcohol dependence. AUDIT-C is an abbreviated form consisting of 3 questions.

FAST is a 4-item questionnaire with a minimum score of 0 and a maximum score of 16. The score for hazardous drinking is 3 or more. Over 50% of people will be classified using just the first question, which asks how often the individual has had eight or more drinks on one occasion (or six or more drinks for women).

CAGE is a well-known screening test, but recent research has questioned its value. Two or more positive answers are generally considered a ‘positive’ result. The questions ask if the individual has ever felt the need to cut down on their drinking, if people have annoyed them by criticizing their drinking, if they have ever felt guilty about their drinking, and if they have ever had a drink in the morning to get rid of a hangover.

To diagnose alcohol dependence, the ICD-10 definition requires three or more of the following: compulsion to drink, difficulties controlling alcohol consumption, physiological withdrawal, tolerance to alcohol, neglect of alternative activities to drinking, and persistent use of alcohol despite evidence of harm.

Overall, using screening tools and diagnostic criteria can help healthcare professionals identify individuals with alcohol problem drinking and provide appropriate interventions and support.

Selective serotonin reuptake inhibitors (SSRIs) are commonly used as the first-line treatment for depression. Citalopram and fluoxetine are the preferred SSRIs, while sertraline is recommended for patients who have had a myocardial infarction. However, caution should be exercised when prescribing SSRIs to children and adolescents. Gastrointestinal symptoms are the most common side-effect, and patients taking SSRIs are at an increased risk of gastrointestinal bleeding. Patients should also be aware of the possibility of increased anxiety and agitation after starting a SSRI. Fluoxetine and paroxetine have a higher propensity for drug interactions.

The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a warning regarding the use of citalopram due to its association with dose-dependent QT interval prolongation. As a result, citalopram and escitalopram should not be used in patients with congenital long QT syndrome, known pre-existing QT interval prolongation, or in combination with other medicines that prolong the QT interval. The maximum daily dose of citalopram is now 40 mg for adults, 20 mg for patients older than 65 years, and 20 mg for those with hepatic impairment.

When initiating antidepressant therapy, patients should be reviewed by a doctor after 2 weeks. Patients under the age of 25 years or at an increased risk of suicide should be reviewed after 1 week. If a patient responds well to antidepressant therapy, they should continue treatment for at least 6 months after remission to reduce the risk of relapse. When stopping a SSRI, the dose should be gradually reduced over a 4 week period, except for fluoxetine. Paroxetine has a higher incidence of discontinuation symptoms, including mood changes, restlessness, difficulty sleeping, unsteadiness, sweating, gastrointestinal symptoms, and paraesthesia.

When considering the use of SSRIs during pregnancy, the benefits and risks should be weighed. Use during the first trimester may increase the risk of congenital heart defects, while use during the third trimester can result in persistent pulmonary hypertension of the newborn. Paroxetine has an increased risk of congenital malformations, particularly in the first trimester.

The Mental Health Act (MHA) has several sections that allow for compulsory admission and treatment of individuals with mental disorders. Section 5(2) can only be used for inpatients and is implemented by the Responsible Clinician or their designated deputy. It lasts for 72 hours and should be followed by a formal Mental Health Act assessment for consideration of detention under Section 2 or 3. Section 2 allows for compulsory admission and assessment of individuals who cannot be safely assessed in the community and refuse voluntary admission. It requires an application from the patient’s nearest relative or an Approved Mental Health Professional (AMHP) and two medical recommendations. It lasts up to 28 days and can be appealed within 14 days of admission. Section 136 allows the police to remove individuals from public places and take them to a place of safety, such as a Mental Health Unit or Accident and Emergency. Section 3 allows for compulsory admission and treatment of individuals who pose risks to self or others and refuse voluntary admission. It requires an application from the patient’s nearest relative or an AMHP and two medical recommendations. It lasts up to 6 months and can be appealed within the first 6 months and then once a year. Section 4 is an emergency section that allows for detention in hospital for up to 72 hours and requires an application from an AMHP or the patient’s nearest relative and one medical recommendation. It can be converted to Section 2 if a second medical recommendation is obtained within 72 hours and should only be used in urgent cases.

Weight gain is a common side effect of atypical antipsychotics.

Atypical antipsychotics are now recommended as the first-line treatment for patients with schizophrenia, as per the 2005 NICE guidelines. These medications have the advantage of significantly reducing extrapyramidal side-effects. However, they can also cause adverse effects such as weight gain, hyperprolactinaemia, and in the case of clozapine, agranulocytosis. The Medicines and Healthcare products Regulatory Agency has issued warnings about the increased risk of stroke and venous thromboembolism when antipsychotics are used in elderly patients. Examples of atypical antipsychotics include clozapine, olanzapine, risperidone, quetiapine, amisulpride, and aripiprazole.

Clozapine, one of the first atypical antipsychotics, carries a significant risk of agranulocytosis and requires full blood count monitoring during treatment. Therefore, it should only be used in patients who are resistant to other antipsychotic medication. The BNF recommends introducing clozapine if schizophrenia is not controlled despite the sequential use of two or more antipsychotic drugs, one of which should be a second-generation antipsychotic drug, each for at least 6-8 weeks. Adverse effects of clozapine include agranulocytosis, neutropaenia, reduced seizure threshold, constipation, myocarditis, and hypersalivation. Dose adjustment of clozapine may be necessary if smoking is started or stopped during treatment.

Fluoxetine is the preferred SSRI for children and adolescents.

Selective serotonin reuptake inhibitors (SSRIs) are commonly used as the first-line treatment for depression. Citalopram and fluoxetine are the preferred SSRIs, while sertraline is recommended for patients who have had a myocardial infarction. However, caution should be exercised when prescribing SSRIs to children and adolescents. Gastrointestinal symptoms are the most common side-effect, and patients taking SSRIs are at an increased risk of gastrointestinal bleeding. Patients should also be aware of the possibility of increased anxiety and agitation after starting a SSRI. Fluoxetine and paroxetine have a higher propensity for drug interactions.

The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a warning regarding the use of citalopram due to its association with dose-dependent QT interval prolongation. As a result, citalopram and escitalopram should not be used in patients with congenital long QT syndrome, known pre-existing QT interval prolongation, or in combination with other medicines that prolong the QT interval. The maximum daily dose of citalopram is now 40 mg for adults, 20 mg for patients older than 65 years, and 20 mg for those with hepatic impairment.

When initiating antidepressant therapy, patients should be reviewed by a doctor after 2 weeks. Patients under the age of 25 years or at an increased risk of suicide should be reviewed after 1 week. If a patient responds well to antidepressant therapy, they should continue treatment for at least 6 months after remission to reduce the risk of relapse. When stopping a SSRI, the dose should be gradually reduced over a 4 week period, except for fluoxetine. Paroxetine has a higher incidence of discontinuation symptoms, including mood changes, restlessness, difficulty sleeping, unsteadiness, sweating, gastrointestinal symptoms, and paraesthesia.

When considering the use of SSRIs during pregnancy, the benefits and risks should be weighed. Use during the first trimester may increase the risk of congenital heart defects, while use during the third trimester can result in persistent pulmonary hypertension of the newborn. Paroxetine has an increased risk of congenital malformations, particularly in the first trimester.

Atypical antipsychotics are now recommended as the first-line treatment for patients with schizophrenia, as per the 2005 NICE guidelines. These medications have the advantage of significantly reducing extrapyramidal side-effects. However, they can also cause adverse effects such as weight gain, hyperprolactinaemia, and in the case of clozapine, agranulocytosis. The Medicines and Healthcare products Regulatory Agency has issued warnings about the increased risk of stroke and venous thromboembolism when antipsychotics are used in elderly patients. Examples of atypical antipsychotics include clozapine, olanzapine, risperidone, quetiapine, amisulpride, and aripiprazole.

Clozapine, one of the first atypical antipsychotics, carries a significant risk of agranulocytosis and requires full blood count monitoring during treatment. Therefore, it should only be used in patients who are resistant to other antipsychotic medication. The BNF recommends introducing clozapine if schizophrenia is not controlled despite the sequential use of two or more antipsychotic drugs, one of which should be a second-generation antipsychotic drug, each for at least 6-8 weeks. Adverse effects of clozapine include agranulocytosis, neutropaenia, reduced seizure threshold, constipation, myocarditis, and hypersalivation. Dose adjustment of clozapine may be necessary if smoking is started or stopped during treatment.

Mirtazapine is more likely to cause sedation at lower doses (e.g. 15mg) than at higher doses (e.g. 45mg).

The appropriate course of action is to increase the mirtazapine dose to 30mg at night. If there has been no improvement in symptoms after four weeks, it is reasonable to increase the dose to the usual minimum effective dose. It is important to note that sedation typically decreases with higher doses of mirtazapine due to increased noradrenergic activity.

If the patient does not respond to or cannot tolerate an increase in mirtazapine, switching to an alternative medication such as fluoxetine or venlafaxine may be considered. However, it is advisable to try the usual minimum effective dose of mirtazapine before deciding to switch medications.

Amitriptyline and other TCAs are no longer commonly used in the treatment of depression due to the risk of overdose.

In cases of severe depression, depression that does not respond to primary care management, or suspected bipolar disorder, it is recommended to seek a secondary care opinion.

Mirtazapine: An Effective Antidepressant with Fewer Side Effects

Mirtazapine is an antidepressant medication that functions by blocking alpha2-adrenergic receptors, which leads to an increase in the release of neurotransmitters. Compared to other antidepressants, mirtazapine has fewer side effects and interactions, making it a suitable option for older individuals who may be more susceptible to adverse effects or are taking other medications.

Mirtazapine has two side effects that can be beneficial for older individuals who are experiencing insomnia and poor appetite. These side effects include sedation and an increased appetite. As a result, mirtazapine is typically taken in the evening to help with sleep and to stimulate appetite.

Overall, mirtazapine is an effective antidepressant that is well-tolerated by many individuals. Its unique side effects make it a valuable option for older individuals who may have difficulty sleeping or eating.